Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay
about
CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjectsEfficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cellsAntigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cellsBeyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues.Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motifRapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection.Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine designThe HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individualsDominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infectionComprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes.Adaptation of CD8 T cell responses to changing HIV-1 sequences in a cohort of HIV-1 infected individuals not selected for a certain HLA allele.Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences.Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains.Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusCellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and childrenFine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02Paediatric non-progression following grandmother-to-child HIV transmissionDifferential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.Comparison of experimental fine-mapping to in silico prediction results of HIV-1 epitopes reveals ongoing need for mapping experiments.Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32Widespread impact of HLA restriction on immune control and escape pathways of HIV-1Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire.Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities.HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memoryImpaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressorTreatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.Immunization with one Theileria parva strain results in similar level of CTL strain-specificity and protection compared to immunization with the three-component Muguga cocktail in MHC-matched animals.
P2860
Q24798701-FE760491-CD94-4B30-ACCD-49DA0F151770Q28748976-4623D3BB-FA4B-46B8-8413-1E4413668515Q28754733-D5B5584B-4F5F-46CD-9D52-EB3778E79C21Q30332080-FDD12230-4678-4959-9438-1E8F48BD0627Q33836117-AFB44B09-68DB-4F10-9A64-F4DB1F256825Q33836176-FAC277B0-F821-4D2C-B992-E9E5E1117384Q33843340-564ABE76-BFB5-4EAB-81B8-5B15D50DB168Q33845527-7C916DA2-A70F-45DA-81DE-20347123907FQ34104267-0E2829EA-FDCC-4995-B7D4-769F9AF39669Q34358162-2A17BB79-77DA-4E01-A3E3-76D2E6EE14CAQ34361731-BBED7314-A2FF-4685-B912-CCC8BCCF3483Q34468117-57EF4D8E-B9C8-402B-80C6-8AB7D23EED47Q34531858-832DBA61-E887-4637-8A99-6708C916AD6CQ34539993-836880D9-2C04-4BCB-889F-72566B6B7689Q34999197-8424357A-E651-4DD7-824A-D631A1A1AE8BQ35061003-9323849B-B9FC-4BEB-82B4-029701858DE8Q35149407-4AF3D513-615F-463A-BF53-CB73DC83AE55Q35149956-7581DB8C-EC0E-4AA9-A343-77F0EC7418B8Q35150143-DDEEB4C7-C735-42E0-86DD-31D6AF1248CEQ36228343-E3687034-A563-4FBD-942C-CB2E4C0D06E7Q36369035-E371B947-C26B-498C-BCC1-D1456E6AFFC3Q36399423-F5212828-52A3-4C4F-B021-3A60EEF82C74Q36404594-F30DD531-AE97-4CA6-A316-674F692D3E02Q36909497-BF128479-101C-44B8-B632-EA8C27E67CEFQ36943282-90CA5B45-DD5D-4A8D-9BBA-7B7DC5320FFBQ37074610-0EDE13D6-831C-4235-B8E3-68F382AD0B28Q37243687-FED3F89B-4A4D-4D87-9222-3ECA3FA5D8FAQ37714013-0D60EA9F-7DEB-4FBF-886D-7E601512629CQ39005162-342F9E75-3DD8-49E7-A964-1885C9D1783DQ39737687-9F2519BF-1B46-425F-813D-7610A473268DQ40054946-8923A55E-9C9E-4F6B-B090-BB76E7294F22Q40071847-90566F7D-336D-4193-9AB1-243A6D2D49B9Q41456115-03D41264-C3B2-434F-B74D-93364BB453A9Q41814777-D128AFFF-FB52-4581-8DB1-F517D2CE2F56Q41880425-56733241-8DC9-4F52-9DAA-EFCCAE36AF6FQ41919259-1543F6B4-40FF-4447-B871-000DAC2F0FE8Q42258606-550FF122-4C2B-4743-9E97-B17A061B3ABDQ42390737-6FED5B3D-7A12-4E01-9AE4-3B2447375CC0Q54211966-90C9EC68-A65A-4FBE-8D3E-26AE450E022FQ54223809-F08B801F-9C2F-4D4C-A592-30A8694C4AFE
P2860
Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Identification of dominant opt ...... enzyme-linked immunospot assay
@ast
Identification of dominant opt ...... enzyme-linked immunospot assay
@en
type
label
Identification of dominant opt ...... enzyme-linked immunospot assay
@ast
Identification of dominant opt ...... enzyme-linked immunospot assay
@en
prefLabel
Identification of dominant opt ...... enzyme-linked immunospot assay
@ast
Identification of dominant opt ...... enzyme-linked immunospot assay
@en
P2093
P2860
P1433
P1476
Identification of dominant opt ...... enzyme-linked immunospot assay
@en
P2093
B D Walker
E S Rosenberg
K McIntosh
M A Altfeld
M N Phillips
P J Goulder
R L Eldridge
R P Sekaly
P2860
P304
P356
10.1128/JVI.74.18.8541-8549.2000
P577
2000-09-01T00:00:00Z